If you run a small developer with more ambition than headcount, the most useful thing to come out of Britain this spring is not the press-release language about the UK being “the best place in the world” for research. It is a quieter, more practical opening: a fast-track route that rewards work you have already paid for somewhere else. As of April 28, the Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025 are in force, and tucked inside the package is a notification scheme that, used deliberately, can turn the UK into a fast second (or third) stop on a development plan rather than another full-fat regulatory slog.
5 min read
MHRA
Watchdog Wednesday: The UK’s Express Lane for Latecomers
The UK's new "notifiable trial" route can shave weeks off your timeline, but only if you sequence your jurisdictions like a chess player rather than a tourist.
